In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name products.
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.
At 23 years of follow-up, the cumulative incidence of death was higher among patients in the watchful waiting group compared with those in the radical prostatectomy group.
"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma